Effect of rabbit ATG PK on outcomes after TCR-αβ/CD19-depleted pediatric haploidentical HCT for hematologic malignancy.

Saved in:
Bibliographic Details
Title: Effect of rabbit ATG PK on outcomes after TCR-αβ/CD19-depleted pediatric haploidentical HCT for hematologic malignancy.
Authors: Dvorak CC; Division of Pediatric Allergy, Immunology, and Bone Marrow Transplantation, Department of Clinical Pharmacy, University of California San Francisco Benioff Children's Hospitals, San Francisco, CA., Long-Boyle JR; Division of Pediatric Allergy, Immunology, and Bone Marrow Transplantation, Department of Clinical Pharmacy, University of California San Francisco Benioff Children's Hospitals, San Francisco, CA., Holbrook-Brown L; Division of Hematology and Oncology, Section of Transplantation Intermountain Primary Children's Hospital, Huntsman Cancer Institute, Spencer Fox Eccles School of Medicine at The University of Utah, Salt Lake City, UT., Abdel-Azim H; Cancer Center, Children's Hospital and Medical Center, Loma Linda University School of Medicine, Loma Linda, CA., Bertaina A; Division of Pediatric Hematology, Oncology, Stem Cell Transplantation & Regenerative Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA., Vatsayan A; Division of Blood and Marrow Transplantation, Children's National Hospital, George Washington University School of Medicine and Health Sciences, Washington, DC., Talano JA; Division of Pediatric Hematology, Oncology, and Blood and Marrow Transplant, Medical College of Wisconsin, Milwaukee, WI., Bunin N; Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA., Anderson E; Division of Pediatric Hematology-Oncology, Rady Children's Hospital, University of California San Diego, San Diego, CA., Flower A; Division of Pediatric Hematology, Oncology, and Stem Cell Transplantation, New York Medical College, Valhalla, NY., Lalefar N; Division of Hematology, University of California San Francisco Benioff Children's Hospitals, Oakland, CA., Higham CS; Division of Pediatric Allergy, Immunology, and Bone Marrow Transplantation, Department of Clinical Pharmacy, University of California San Francisco Benioff Children's Hospitals, San Francisco, CA., Kapoor N; Division of Pediatric Hematology, Oncology, and Transplantation and Cellular Therapy, University of Southern California Children's Hospital Los Angeles, Los Angeles, CA., Klein O; Division of Pediatric Hematology, Oncology, Stem Cell Transplantation & Regenerative Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA., Odinakachukwu MC; Division of Blood and Marrow Transplantation, Children's National Hospital, George Washington University School of Medicine and Health Sciences, Washington, DC., Cho S; Division of Hematology and Oncology, Section of Transplantation Intermountain Primary Children's Hospital, Huntsman Cancer Institute, Spencer Fox Eccles School of Medicine at The University of Utah, Salt Lake City, UT., Jacobsohn DA; Division of Blood and Marrow Transplantation, Children's National Hospital, George Washington University School of Medicine and Health Sciences, Washington, DC., Collier W; Division of Biostatistics, Department of Population and Public Health Sciences, University of Southern California, Los Angeles, CA., Pulsipher MA; Division of Hematology and Oncology, Section of Transplantation Intermountain Primary Children's Hospital, Huntsman Cancer Institute, Spencer Fox Eccles School of Medicine at The University of Utah, Salt Lake City, UT.
Source: Blood advances [Blood Adv] 2024 Dec 10; Vol. 8 (23), pp. 6003-6014.
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study
Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2473-9537
DOI:10.1182/bloodadvances.2024012670